vs

Side-by-side financial comparison of MNTN, Inc. (MNTN) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

MNTN, Inc. is the larger business by last-quarter revenue ($70.0M vs $35.5M, roughly 2.0× RECURSION PHARMACEUTICALS, INC.). MNTN, Inc. runs the higher net margin — 9.2% vs -304.2%, a 313.4% gap on every dollar of revenue.

MNTN Inc. is a U.S.-headquartered advertising technology firm specializing in performance-driven connected TV (CTV) advertising solutions. It serves e-commerce, retail, and consumer goods brands, helping clients accurately measure ad campaign ROI and reach targeted audiences across streaming TV platforms in North American and European markets.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

MNTN vs RXRX — Head-to-Head

Bigger by revenue
MNTN
MNTN
2.0× larger
MNTN
$70.0M
$35.5M
RXRX
Higher net margin
MNTN
MNTN
313.4% more per $
MNTN
9.2%
-304.2%
RXRX

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
MNTN
MNTN
RXRX
RXRX
Revenue
$70.0M
$35.5M
Net Profit
$6.4M
$-108.1M
Gross Margin
78.9%
59.8%
Operating Margin
10.8%
-304.8%
Net Margin
9.2%
-304.2%
Revenue YoY
681.7%
Net Profit YoY
39.6%
EPS (diluted)
$0.08
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MNTN
MNTN
RXRX
RXRX
Q4 25
$35.5M
Q3 25
$70.0M
$5.2M
Q2 25
$68.5M
$19.2M
Q1 25
$14.7M
Q4 24
$4.5M
Q3 24
$26.1M
Q2 24
$14.4M
Q1 24
$13.8M
Net Profit
MNTN
MNTN
RXRX
RXRX
Q4 25
$-108.1M
Q3 25
$6.4M
$-162.3M
Q2 25
$-26.2M
$-171.9M
Q1 25
$-202.5M
Q4 24
$-178.9M
Q3 24
$-95.8M
Q2 24
$-97.5M
Q1 24
$-91.4M
Gross Margin
MNTN
MNTN
RXRX
RXRX
Q4 25
59.8%
Q3 25
78.9%
-183.8%
Q2 25
76.8%
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
MNTN
MNTN
RXRX
RXRX
Q4 25
-304.8%
Q3 25
10.8%
-3327.6%
Q2 25
5.4%
-916.8%
Q1 25
-1297.9%
Q4 24
-4042.4%
Q3 24
-377.1%
Q2 24
-697.4%
Q1 24
-698.4%
Net Margin
MNTN
MNTN
RXRX
RXRX
Q4 25
-304.2%
Q3 25
9.2%
-3135.3%
Q2 25
-38.3%
-894.2%
Q1 25
-1373.3%
Q4 24
-3935.5%
Q3 24
-367.5%
Q2 24
-676.6%
Q1 24
-662.4%
EPS (diluted)
MNTN
MNTN
RXRX
RXRX
Q4 25
$-0.17
Q3 25
$0.08
$-0.36
Q2 25
$-0.65
$-0.41
Q1 25
$-0.50
Q4 24
$-0.56
Q3 24
$-0.34
Q2 24
$-0.40
Q1 24
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MNTN
MNTN
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$179.2M
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$266.7M
$1.1B
Total Assets
$335.9M
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MNTN
MNTN
RXRX
RXRX
Q4 25
$743.3M
Q3 25
$179.2M
$659.8M
Q2 25
$175.2M
$525.1M
Q1 25
$500.5M
Q4 24
$594.4M
Q3 24
$427.6M
Q2 24
$474.3M
Q1 24
$296.3M
Total Debt
MNTN
MNTN
RXRX
RXRX
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
MNTN
MNTN
RXRX
RXRX
Q4 25
$1.1B
Q3 25
$266.7M
$1.0B
Q2 25
$238.9M
$919.1M
Q1 25
$933.9M
Q4 24
$1.0B
Q3 24
$524.6M
Q2 24
$584.4M
Q1 24
$401.2M
Total Assets
MNTN
MNTN
RXRX
RXRX
Q4 25
$1.5B
Q3 25
$335.9M
$1.4B
Q2 25
$337.0M
$1.3B
Q1 25
$1.3B
Q4 24
$1.4B
Q3 24
$726.5M
Q2 24
$775.9M
Q1 24
$557.8M
Debt / Equity
MNTN
MNTN
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MNTN
MNTN
RXRX
RXRX
Operating Cash FlowLast quarter
$9.3M
$-46.1M
Free Cash FlowOCF − Capex
$-47.3M
FCF MarginFCF / Revenue
-133.1%
Capex IntensityCapex / Revenue
3.5%
Cash ConversionOCF / Net Profit
1.45×
TTM Free Cash FlowTrailing 4 quarters
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MNTN
MNTN
RXRX
RXRX
Q4 25
$-46.1M
Q3 25
$9.3M
$-117.4M
Q2 25
$17.6M
$-76.4M
Q1 25
$-132.0M
Q4 24
$-115.4M
Q3 24
$-59.2M
Q2 24
$-82.2M
Q1 24
$-102.3M
Free Cash Flow
MNTN
MNTN
RXRX
RXRX
Q4 25
$-47.3M
Q3 25
$-117.6M
Q2 25
$-79.6M
Q1 25
$-133.8M
Q4 24
$-116.7M
Q3 24
$-63.8M
Q2 24
$-83.4M
Q1 24
$-109.0M
FCF Margin
MNTN
MNTN
RXRX
RXRX
Q4 25
-133.1%
Q3 25
-2272.5%
Q2 25
-413.9%
Q1 25
-907.4%
Q4 24
-2567.7%
Q3 24
-244.6%
Q2 24
-578.5%
Q1 24
-789.9%
Capex Intensity
MNTN
MNTN
RXRX
RXRX
Q4 25
3.5%
Q3 25
4.7%
Q2 25
16.4%
Q1 25
12.4%
Q4 24
28.6%
Q3 24
17.5%
Q2 24
8.2%
Q1 24
48.2%
Cash Conversion
MNTN
MNTN
RXRX
RXRX
Q4 25
Q3 25
1.45×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons